Market Overview

Markets are set to open mixed-to-positive Friday as geopolitical tailwinds from Trump signaling an imminent Iran deal buoy risk appetite, while the SpaceX IPO debut (indicated +27%) dominates attention and could siphon liquidity from other growth names. Lithium/battery stocks continue their multi-week outperformance (BATT +25% YTD vs SPY +11%), and AI/data center themes remain firmly bid after Thursday’s +1.75% S&P rally. The “buyer’s dream” pullback narrative from Manulife’s strategist is giving institutional cover to add risk.

Claude’s Call

UP — The Iran de-escalation removes a tail risk that wiped $1.2T from markets earlier this week, and the SpaceX IPO euphoria should keep animal spirits elevated through Friday’s session, though I’d expect gains to be modest (+0.3-0.5%) as we digest Thursday’s outsized move.

Top Movers

RZLV (+14.7%) — $2.87 → $3.40 (+18.5% upside) Thesis: Rezolve AI is riding a triple catalyst — Microsoft veteran CMO hire, reaffirmed $360M 2026 revenue guidance with 1,000+ enterprise customers, and the TCS partnership expanding distribution. At $2.87, this is still a sub-$3 AI commerce play with credible partnerships, but the RSI at 10.05 (extremely oversold even before this bounce) suggests this is a dead-cat bounce off deeply depressed levels rather than a fresh breakout. The 24.6% weekly gain says shorts are covering. Levels: Exit at $3.40 (prior consolidation zone). Support at $2.50 (recent weekly low).

BVC (+9.2%) — $13.99 → $15.50 (+10.8% upside) Thesis: BitVentures is ripping +38.5% on the week with no clear company-specific catalyst — this looks like crypto/fintech sympathy trading. The stock cratered 22% in a single January session and traded at a 99.9x P/B, so this is speculative momentum in a thinly traded name. RSI at 37.9 gives room to run technically, but the lack of fundamental catalyst makes this a momentum rental, not an investment. Levels: Exit at $15.50 (pre-January crash level). Support at $12.80 (breakout level from this week).

CPRI (+7.2%) — $21.17 → $24.00 (+13.4% upside) Thesis: Capri Holdings (Michael Kors, Jimmy Choo, Versace) is bouncing off extreme oversold levels (RSI 10.4) after UBS flagged tariff and macro risks to the FY27 recovery. The footwear repositioning toward casual is the right strategic move but will take quarters to show up. At $21, this is a deep-value luxury play trading well below the failed Tapestry merger price — the market is pricing in continued deterioration that may already be in the stock. Levels: Exit at $24.00 (50-day MA area). Support at $19.75 (52-week low zone).

ATEX (+4.2%) — $83.40 → $95.00 (+13.9% upside) Thesis: Anterix just reported a Q4 earnings beat — revenue +41% YoY on spectrum agreement gains, loss narrower than expected by 27%, and management highlighted accelerating utility demand for 900 MHz spectrum. This is a real fundamental catalyst with strong cash flow commentary. The +25% weekly gain suggests the market is re-rating this name higher, and at RSI 48 there’s no overbought concern. Levels: Exit at $95.00 (prior 6-month high). Support at $75.00 (pre-earnings gap level).

CIFR (+4.1%) — $23.76 → $28.00 (+17.8% upside) Thesis: Cipher Digital is an AI data center play getting Jefferies initiation coverage, Morgan Stanley targets (even if trimmed to $48.5), and benefiting from the broader CoreWeave/Anthropic data center funding boom. RSI at 14.9 is absurdly oversold — this stock is up 620% over the past year but has pulled back hard recently, creating a potential re-entry point as the AI infrastructure buildout remains early innings. Levels: Exit at $28.00 (recent support-turned-resistance). Support at $22.00 (this week’s low).

NRIX (+5.2%) — $17.86 → $21.00 (+17.6% upside) Thesis: Nurix just inked a $2.3B deal with Roche for its BTK-degrading drug bex-deg — this is a transformational partnership for a small biotech. The stock bounced off its 50-day line on the news, and the 22% weekly gain reflects the market properly pricing in milestone/royalty optionality. Deal economics of this magnitude in a $17 stock suggest significant upside if clinical milestones hit. Levels: Exit at $21.00 (measured move target from breakout). Support at $15.50 (50-day MA).

ELVN (+3.0%) — $41.13 → $48.00 (+16.7% upside) Thesis: Enliven Therapeutics reported positive Phase 1 CML data and FDA alignment on Phase 3 trial design — this is a textbook clinical-stage catalyst with regulatory de-risking. The +18.5% weekly gain is the market pricing in reduced binary risk as the company moves toward registration. Clinical biotechs that get FDA alignment on pivotal trial design typically re-rate 30-50% as the path to approval crystallizes. Levels: Exit at $48.00 (next resistance from prior range). Support at $36.00 (pre-data level).

SQM (+2.8%) — $82.69 → $95.00 (+14.9% upside) Thesis: SQM is the purest large-cap lithium play benefiting from the battery/EV thematic trade (BATT ETF crushing SPY). Scotiabank raised PT to $105, Q1 EPS surged from $0.48 to $1.28 YoY, and the RSI at 0.91 is the most extreme oversold reading on this entire list — suggesting a massive mean-reversion bounce is underway. The lithium price recovery is structural, not cyclical. Levels: Exit at $95.00 (Scotiabank’s implied fair value zone). Support at $78.00 (recent consolidation base).

ANF (+2.7%) — $92.50 → $105.00 (+13.5% upside) Thesis: Abercrombie bounced sharply after Trump reversed the Iran military escalation that had hammered consumer discretionary earlier this week. RSI at 11.2 after a -21.4% six-month decline means this is deeply oversold — analysts still have fair value estimates at $111+ and Americas comps are growing 3%. The tariff overhang is real but largely priced in at these levels. Levels: Exit at $105.00 (analyst consensus zone). Support at $85.00 (recent low).

WGS (+3.8%) — $62.12 → $72.00 (+15.9% upside) Thesis: GeneDx is getting aggressive insider buying (Eli Casdin loading up) despite a Q1 miss and guidance cut — smart money is looking through the noise. RSI at 8.0 is the second-most oversold name here, and the 19% weekly bounce suggests the class action lawsuit overhang is being digested. Genomics/precision medicine is a secular theme with staying power, and insiders buying after bad news is historically one of the strongest buy signals. Levels: Exit at $72.00 (pre-earnings gap fill). Support at $55.00 (post-guidance-cut low).

Headlines to Watch

  • SpaceX IPO indicated +27% at open — This could be a sentiment bellwether; if it fades, retail euphoria is exhausted and broader growth names may suffer sympathetic selling.
  • Trump signals Iran deal “coming soon” — Removes the geopolitical premium that wiped $1.2T this week; energy stocks may give back gains while airlines/consumer discretionary benefit.
  • BATT ETF up 25% vs SPY 11% YTD — Lithium/battery theme is the real rotation trade of 2026; SQM, LAR, and ELVR are direct beneficiaries with room to run.
  • Roche inks $2.3B Nurix deal — Validates targeted protein degradation as a platform; watch for M&A contagion in small-cap biotech names with similar modalities.
  • Google backs $35B Anthropic AI infrastructure deal — The hyperscaler capex arms race shows no signs of slowing; CIFR and data center picks-and-shovels plays remain in the sweet spot.
  • Cathie Wood dumps $200M+ across 20 stocks ahead of SpaceX IPO — ARK’s portfolio rebalancing creates forced selling in TWST and others; these are liquidity-driven dips, not fundamental changes.
  • Wall Street strategist calls pullback a “buyer’s dream” — Institutional cover to add risk suggests dip-buying continues; but when everyone agrees it’s a buying opportunity, it usually isn’t as clean as it seems.

Claude’s Top Picks

ATEX (+4.2% today, +25.2% week) — $83.40 → $95.00 (+13.9% upside) Valuation: Trading at a premium to utility peers but justified by 41% revenue growth and unique spectrum monopoly position — there are no direct comps for licensed 900 MHz infrastructure plays. Upside: Accelerating utility adoption, new non-utility use cases, and strong Q4 cash flow create a multi-quarter re-rating narrative with visible revenue ramps ahead. Risk: Spectrum monetization has historically been lumpy; one delayed contract signing could create a gap quarter that spooks momentum investors.

CIFR (+4.1% today, +5.8% week) — $23.76 → $28.00 (+17.8% upside) Valuation: RSI of 14.9 after a pullback from highs suggests the stock is deeply discounted relative to its own recent history; Jefferies initiation and Morgan Stanley’s $48.5 target imply 100%+ upside from here. Upside: AI data center capex is accelerating (Google/Anthropic $35B deal this week), and CIFR is a direct beneficiary with Wall Street consensus firmly bullish. Risk: The stock is up 620% in a year — any macro risk-off event could trigger violent profit-taking in the most extended AI names.

ELVN (+3.0% today, +18.5% week) — $41.13 → $48.00 (+16.7% upside) Valuation: Clinical-stage biotech with positive Phase 1 data and FDA Phase 3 alignment is still valued below the typical de-risked CML asset in the current M&A environment. Upside: FDA alignment on pivotal trial design is the single biggest de-risking event for a clinical-stage name; this removes the “will they accept the endpoint?” overhang entirely. Risk: Binary clinical risk remains — Phase 3 failure would wipe 60%+ regardless of Phase 1 signals.

SQM (+2.8% today, +9.6% week) — $82.69 → $95.00 (+14.9% upside) Valuation: EPS tripled YoY ($0.48 → $1.28) yet the stock trades at a fraction of its 2022 lithium boom highs; Scotiabank’s $105 target implies significant undervaluation vs. the earnings trajectory. Upside: Lithium price recovery is structural (EV adoption + grid storage), BATT ETF outperformance is attracting rotation flows, and RSI 0.91 is screaming mean-reversion. Risk: China lithium oversupply could cap price recovery; SQM’s Chile operations face ongoing royalty/regulatory uncertainty.

NRIX (+5.2% today, +22.0% week) — $17.86 → $21.00 (+17.6% upside) Valuation: A $2.3B Roche partnership on a ~$1.5B market cap biotech represents transformational economics; milestone payments alone could exceed current enterprise value. Upside: Roche’s validation of BTK degradation as a therapeutic approach opens multiple follow-on indications and positions NRIX as an acquisition target. Risk: Biotech deal economics are back-loaded; if bex-deg fails in later trials, milestone payments evaporate and the stock reverts to pre-deal levels.

Avoid

RZLV (+14.7%) — Despite the exciting AI narrative and triple catalyst, this is a sub-$3 stock with an RSI of 10 that screams “relief rally off the floor” rather than sustainable breakout; the $360M revenue guidance needs to actually be delivered before this deserves a chase above $3.

BVC (+9.2%, +38.5% week) — No discernible fundamental catalyst for a nearly 40% weekly move in a thinly traded financial stock with a 99.9x P/B multiple; this is pure speculative momentum that could reverse violently on any broad market weakness.

TWST (+3.3%) — Cathie Wood is actively dumping shares ($200M+ in ARK selling across names including TWST) ahead of the SpaceX IPO, and insiders (CEO and CLO) have sold $2M+ in shares recently; when both the largest institutional holder and management are selling simultaneously, the risk/reward for longs deteriorates significantly.

WSB Sentiment Check

SPCX — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — This is clearly a SpaceX IPO proxy/ETF play with 882 mentions dominating WSB ahead of today’s debut. The +27% indicated open justifies bullishness short-term, but IPO-day euphoria historically fades within 1-2 weeks as lockup dynamics and reality set in. Play it for the pop, don’t marry it.

MSFT — WSB says: BULLISH (80% bullish) Claude says: AGREE — Microsoft is a core AI infrastructure beneficiary with Azure growth re-accelerating, and the broader chipmaker/AI rally supports this. WSB is right that MSFT is the “boring” AI play with the best risk-adjusted setup among megacaps. Not contrarian, but correct.

MU — WSB says: MIXED (55% bullish) Claude says: AGREE WITH MIXED — Micron is always a cyclical knife-catch debate. Memory pricing is recovering but the stock tends to look cheapest at cycle peaks and expensive at troughs. The 55% split reflects genuine uncertainty about whether we’re early or late in the HBM/AI memory cycle. I’d lean slightly bullish given data center capex acceleration.

SPCE — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — This is likely sympathy trading off SpaceX IPO hype, but Virgin Galactic and SpaceX are completely different businesses (suborbital tourism vs. orbital launch + Starlink). SPCE has a history of spiking on space sentiment and giving it all back. This is the definition of hopium trading on vibes, not fundamentals.

ADBE — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — Adobe likely reported earnings this week (it’s “in focus” per headlines) and the bullish sentiment suggests a beat. Adobe’s AI integration story (Firefly) is real, but valuation has historically capped upside even after strong prints. If you’re buying the post-earnings dip, fine; if you’re chasing +5% after results, the risk/reward is less compelling.

Earnings Scorecard

ATEX — BEAT by ~23-27% on both revenue and EPS | Stock: +25.2% week | Reported: Tuesday After Close The reaction is justified — 41% revenue growth from spectrum agreements with utility customers represents tangible demand acceleration, not one-time gains. Management’s emphasis on new non-utility use cases and stronger balance sheet positions this for continued upside. Buy pullbacks to $75-78.